London
· Delayed Price · Currency is GBP · Price in USD Vanda Pharmaceuticals Statistics
Total Valuation
Vanda Pharmaceuticals has a market cap or net worth of GBP 205.94 million. The enterprise value is -93.11 million.
| Market Cap | 205.94M |
| Enterprise Value | -93.11M |
Important Dates
The next estimated earnings date is Friday, February 7, 2025.
| Earnings Date | Feb 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.24% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 52.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 0.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 7.62 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 1.01 |
Financial Position
The company has a current ratio of 4.85, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.85 |
| Quick Ratio | 4.70 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.06 |
| Interest Coverage | -41.59 |
Financial Efficiency
Return on equity (ROE) is -3.02% and return on invested capital (ROIC) is -4.25%.
| Return on Equity (ROE) | -3.02% |
| Return on Assets (ROA) | -3.64% |
| Return on Capital (ROIC) | -4.25% |
| Revenue Per Employee | 701,474 |
| Profits Per Employee | -60,232 |
| Employee Count | 203 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 9.30 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.74% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +20.74% |
| 50-Day Moving Average | 4.82 |
| 200-Day Moving Average | 5.08 |
| Relative Strength Index (RSI) | 41.70 |
| Average Volume (20 Days) | 1,740 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.08 |
Income Statement
In the last 12 months, Vanda Pharmaceuticals had revenue of GBP 142.40 million and -12.23 million in losses. Loss per share was -0.22.
| Revenue | 142.40M |
| Gross Profit | 133.31M |
| Operating Income | -27.96M |
| Pretax Income | -13.49M |
| Net Income | -12.23M |
| EBITDA | -22.50M |
| EBIT | -27.96M |
| Loss Per Share | -0.22 |
Balance Sheet
The company has 280.73 million in cash and 5.92 million in debt, giving a net cash position of 274.80 million.
| Cash & Cash Equivalents | 280.73M |
| Total Debt | 5.92M |
| Net Cash | 274.80M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 403.81M |
| Book Value Per Share | 6.93 |
| Working Capital | 256.13M |
Cash Flow
In the last 12 months, operating cash flow was -13.19 million and capital expenditures -78.66 million, giving a free cash flow of -91.84 million.
| Operating Cash Flow | -13.19M |
| Capital Expenditures | -78.66M |
| Free Cash Flow | -91.84M |
| FCF Per Share | n/a |
Margins
Gross margin is 93.62%, with operating and profit margins of -19.64% and -8.59%.
| Gross Margin | 93.62% |
| Operating Margin | -19.64% |
| Pretax Margin | -9.48% |
| Profit Margin | -8.59% |
| EBITDA Margin | -15.80% |
| EBIT Margin | -19.64% |
| FCF Margin | n/a |
Dividends & Yields
Vanda Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.24% |
| Shareholder Yield | -0.24% |
| Earnings Yield | -5.94% |
| FCF Yield | -44.60% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Vanda Pharmaceuticals has an Altman Z-Score of 1.93. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.93 |
| Piotroski F-Score | n/a |